{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-114089","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2025-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.278304+00:00","generated_at":"2026-05-17T06:52:36.408571+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clearside Biomedical announces 1-for-15 reverse stock split, authorized shares reduced to 26.7M","bullets":["Reverse stock split at 1-for-15 ratio; effective 5:00 p.m. ET on Sept 12, 2025.","Authorized shares reduced from 400M to 26,666,666; no change to par value.","Trading on split-adjusted basis on Nasdaq Capital Market starting Sept 15, 2025; new CUSIP 185063203.","No fractional shares; cash paid in lieu; proportionate adjustments to stock options, RSUs, warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-114089","json":"https://secwatch.observer/filing/0000950170-25-114089.json","markdown":"https://secwatch.observer/filing/0000950170-25-114089.md","text":"https://secwatch.observer/filing/0000950170-25-114089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025114089/0000950170-25-114089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025114089/clsd-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:52:36.408571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97381b1fe977f24cf4c6bbb5950e07cf90bf5d1c","claim":"Clearside Biomedical, Inc.: Clearside Biomedical filed a Certificate of Amendment to effect a 1-for-15 reverse stock split and reduce authorized common shares from 400,000,000 to 26,666,666 (effective 2025-09-12).","evidence_excerpt":"On September 10, 2025, Clearside Biomedical, Inc. (the “ Company ”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a one-for-fifteen (1-for-15) reverse stock split (the “ Reverse Stock Split ”) of its outstanding common stock and a reduction in the total number of authorized shares of its common stock from 400,000,000 to 26,666,666 (the “ Shares Reduction ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025114089/0000950170-25-114089-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-09-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}